<DOC>
	<DOCNO>NCT01633346</DOCNO>
	<brief_summary>The purpose study know level expression activation state different transcription factor STAT family ( STAT1 , STAT3 , STAT5A , STAT5B , STAT6 ) hematopoietic cell tocilizumab treat patient .</brief_summary>
	<brief_title>Regulation Immune System Response Treatment With Tocilizumab Rheumatoid Arthritis Patients</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Diagnosis moderate severe active RA ≥6 month duration . Patients commence treatment RoActemra® ( tocilizumab ) accordance approve Summary Product Characteristics . Age &gt; 18 year . Body weight ≤150 kg . Nonpregnant , nonnursing female , female childbearing potential must use reliable mean contraception , eg , physical barrier ( patient partner ) , contraceptive pill patch , spermicide barrier , intrauterine device ( IUD ) If female childbearing potential , patient must negative urine screen baseline . If patient receive oral corticosteroid , prednisone dose equivalent must ≤10 mg/day stable ≥28 day prior screen . If patient currently take permit nonbiologic DMARD , dose must stable ≥7 week prior baseline . Willing receive oral folate leucovorin take methotrexate . Patients give write information study consent data collection review . History autoimmune disease inflammatory joint disease RA . Treatment investigational agent within 4 week ( 5 halflives investigational agent , whichever long ) start treatment RoActemra® Pregnant woman nurse ( breastfeed ) mother Major surgery ( include joint surgery ) within 8 week prior screen plan major surgery within 6 month follow randomization . Functional class IV define ACR Classification Functional Status RA ( ie , largely wholly incapacitated patient bedridden confine wheel chair , permit little selfcare ) Treatment rituximab within 6 month screen . Treatment IV gamma globulin , plasmapheresis Prosorba® column within month , investigational celldepleting therapy baseline . Immunization live/attenuated vaccine within 4 week prior baseline . Any previous treatment alkylating agent , cyclophosphamide chlorambucil , total lymphoid irradiation . Treatment : Intraarticular ( IA ) corticosteroid within 8 week prior screen . Intramuscular ( IM ) IV corticosteroid within 12 week prior screen . History severe allergic anaphylactic reaction human , humanize , murine monoclonal antibody . Evidence serious uncontrolled concomitant cardiovascular , nervous system , pulmonary ( include obstructive pulmonary disease ) , renal , hepatic , endocrine ( include uncontrolled diabetes mellitus ) GI disease ( include complicate Evidence active malignant disease , malignancy diagnose within previous 5 year ( include hematological malignancy solid tumor , except non melanoma skin cancer excise cure ) , breast cancer diagnose within previous 5 year . Active TB require treatment within previous 3 year . Patients previously treat TB recurrence past 3 year permit . Patients positive purified protein derivative ( PPD ) tuberculin skin test adequately treat TB must treat latent TB isoniazid ( INH ) 1 month prior enrollment whether vaccinate past . Patients positive PPD ≥5mm screen eligible study unless begin treatment latent TB INH minimum 1 month prior enrollment trial . The required total INH treatment duration 9 month . Patients must negative CXR enrollment . HIVpositive . History alcohol , drug chemical abuse within 6 month prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>